EP Patent

EP0542372A1 — 2-Substituted saccharin derivative proteolytic enzyme inhibitors

Assigned to Sanofi SA · Expires 1993-05-19 · 33y expired

What this patent protects

Novel 2-substituted saccharins which inhibit the enzymatic activity of proteolytic enzymes are useful in the treatment of degenerative diseases and have the formula    wherein:    L is -O-, -S-, -SO- or -SO₂-;    m and n are each independently 0 or 1;    R₁ is substit…

USPTO Abstract

Novel 2-substituted saccharins which inhibit the enzymatic activity of proteolytic enzymes are useful in the treatment of degenerative diseases and have the formula    wherein:    L is -O-, -S-, -SO- or -SO₂-;    m and n are each independently 0 or 1;    R₁ is substituted phenyl, heterocyclyl or substitued heterocyclyl or,    when L is -O- and n is 1, R₁ is cycloheptatrienon-2-yl or,    when L is -S- and n is 1, R₁ is cyano or lower-alkoxythiocarbonyl or,    when L is -SO₂- and n is 1, R₁ is lower-alkyl or trifluoromethyl;    R₂ is hydrogen, lower-alkoxycarbonyl, phenyl or phenylthio; and    R₃ and R₄ are each hydrogen or various substituents,    and processes for preparation and pharmaceutical compositions and method of use thereof are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP0542372A1
Jurisdiction
EP
Classification
Expires
1993-05-19
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.